US Stock MarketDetailed Quotes

IOVA Iovance Biotherapeutics

Watchlist
  • 8.240
  • +0.100+1.23%
Close Nov 21 16:00 ET
  • 8.220
  • -0.020-0.24%
Pre 04:52 ET
2.51BMarket Cap-5567P/E (TTM)

Iovance Biotherapeutics Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
12,384.86%58.55M
12,969.75%31.11M
715K
1.19M
482K
469K
238K
0
0
0
Operating revenue
12,551.16%59.84M
12,969.75%31.11M
--715K
--1.19M
--478K
--473K
--238K
--0
--0
--0
Cost of revenue
817.58%39.82M
1,430.15%31.37M
7.26M
10.76M
4.37M
4.34M
2.05M
0
0
0
Gross profit
583.88%18.73M
85.54%-262K
-6.55M
-9.57M
-3.88M
-3.87M
-1.81M
0
0
0
Operating expense
-5.85%107.8M
-6.12%101.65M
0.29%111.18M
13.07%450.99M
9.66%117.37M
14.04%114.49M
8.56%108.27M
20.87%110.86M
16.39%398.88M
7.61%107.04M
Selling and administrative expenses
46.69%39.55M
80.45%39.57M
11.63%31.39M
2.71%106.92M
13.00%29.9M
-3.33%26.96M
-16.72%21.93M
20.11%28.12M
24.42%104.1M
10.96%26.46M
Research and development costs
-22.03%68.25M
-28.10%62.08M
-3.57%79.78M
16.72%344.08M
8.56%87.47M
20.72%87.53M
17.63%86.35M
21.13%82.73M
13.80%294.78M
6.56%80.57M
Operating profit
24.75%-89.07M
7.42%-101.91M
-6.19%-117.72M
-15.46%-460.56M
-13.29%-121.26M
-17.90%-118.36M
-10.38%-110.09M
-20.87%-110.86M
-16.39%-398.88M
-7.61%-107.04M
Net non-operating interest income expense
19.27%4.01M
8.89%3.36M
-4.25%3.34M
336.95%13.04M
81.60%3.12M
332.18%3.36M
700.26%3.08M
3,188.68%3.49M
561.86%2.99M
1,171.85%1.72M
Non-operating interest income
19.27%4.01M
8.89%3.36M
-4.25%3.34M
336.95%13.04M
81.60%3.12M
332.18%3.36M
700.26%3.08M
3,188.68%3.49M
561.86%2.99M
1,171.85%1.72M
Other net income (expense)
Income before tax
26.04%-85.06M
7.89%-98.56M
-6.53%-114.38M
-13.04%-447.52M
-12.17%-118.14M
-15.44%-115M
-7.71%-107.01M
-17.21%-107.37M
-15.67%-395.89M
-6.03%-105.32M
Income tax
-22.28%-1.52M
-205.66%-1.46M
-1.41M
-3.48M
-1.76M
-1.24M
-477K
0
0
0
Net income
26.56%-83.54M
8.85%-97.1M
-5.22%-112.98M
-12.16%-444.04M
-10.50%-116.38M
-14.20%-113.76M
-7.23%-106.53M
-17.21%-107.37M
-15.67%-395.89M
-6.03%-105.32M
Net income continuous Operations
26.56%-83.54M
8.85%-97.1M
-5.22%-112.98M
-12.16%-444.04M
-10.50%-116.38M
-14.20%-113.76M
-7.23%-106.53M
-17.21%-107.37M
-15.67%-395.89M
-6.03%-105.32M
Minority interest income
Net income attributable to the parent company
26.56%-83.54M
8.85%-97.1M
-5.22%-112.98M
-12.16%-444.04M
-10.50%-116.38M
-14.20%-113.76M
-7.23%-106.53M
-17.21%-107.37M
-15.67%-395.89M
-6.03%-105.32M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
26.56%-83.54M
8.85%-97.1M
-5.22%-112.98M
-12.16%-444.04M
-10.50%-116.38M
-14.20%-113.76M
-7.23%-106.53M
-17.21%-107.37M
-15.67%-395.89M
-6.03%-105.32M
Basic earnings per share
39.13%-0.28
27.66%-0.34
16.00%-0.42
24.10%-1.89
29.69%-0.45
26.98%-0.46
25.40%-0.47
13.79%-0.5
-11.66%-2.49
-1.59%-0.64
Diluted earnings per share
39.13%-0.28
27.66%-0.34
16.00%-0.42
24.10%-1.89
29.69%-0.45
26.98%-0.46
25.40%-0.47
13.79%-0.5
-11.66%-2.49
-1.59%-0.64
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 12,384.86%58.55M12,969.75%31.11M715K1.19M482K469K238K000
Operating revenue 12,551.16%59.84M12,969.75%31.11M--715K--1.19M--478K--473K--238K--0--0--0
Cost of revenue 817.58%39.82M1,430.15%31.37M7.26M10.76M4.37M4.34M2.05M000
Gross profit 583.88%18.73M85.54%-262K-6.55M-9.57M-3.88M-3.87M-1.81M000
Operating expense -5.85%107.8M-6.12%101.65M0.29%111.18M13.07%450.99M9.66%117.37M14.04%114.49M8.56%108.27M20.87%110.86M16.39%398.88M7.61%107.04M
Selling and administrative expenses 46.69%39.55M80.45%39.57M11.63%31.39M2.71%106.92M13.00%29.9M-3.33%26.96M-16.72%21.93M20.11%28.12M24.42%104.1M10.96%26.46M
Research and development costs -22.03%68.25M-28.10%62.08M-3.57%79.78M16.72%344.08M8.56%87.47M20.72%87.53M17.63%86.35M21.13%82.73M13.80%294.78M6.56%80.57M
Operating profit 24.75%-89.07M7.42%-101.91M-6.19%-117.72M-15.46%-460.56M-13.29%-121.26M-17.90%-118.36M-10.38%-110.09M-20.87%-110.86M-16.39%-398.88M-7.61%-107.04M
Net non-operating interest income expense 19.27%4.01M8.89%3.36M-4.25%3.34M336.95%13.04M81.60%3.12M332.18%3.36M700.26%3.08M3,188.68%3.49M561.86%2.99M1,171.85%1.72M
Non-operating interest income 19.27%4.01M8.89%3.36M-4.25%3.34M336.95%13.04M81.60%3.12M332.18%3.36M700.26%3.08M3,188.68%3.49M561.86%2.99M1,171.85%1.72M
Other net income (expense)
Income before tax 26.04%-85.06M7.89%-98.56M-6.53%-114.38M-13.04%-447.52M-12.17%-118.14M-15.44%-115M-7.71%-107.01M-17.21%-107.37M-15.67%-395.89M-6.03%-105.32M
Income tax -22.28%-1.52M-205.66%-1.46M-1.41M-3.48M-1.76M-1.24M-477K000
Net income 26.56%-83.54M8.85%-97.1M-5.22%-112.98M-12.16%-444.04M-10.50%-116.38M-14.20%-113.76M-7.23%-106.53M-17.21%-107.37M-15.67%-395.89M-6.03%-105.32M
Net income continuous Operations 26.56%-83.54M8.85%-97.1M-5.22%-112.98M-12.16%-444.04M-10.50%-116.38M-14.20%-113.76M-7.23%-106.53M-17.21%-107.37M-15.67%-395.89M-6.03%-105.32M
Minority interest income
Net income attributable to the parent company 26.56%-83.54M8.85%-97.1M-5.22%-112.98M-12.16%-444.04M-10.50%-116.38M-14.20%-113.76M-7.23%-106.53M-17.21%-107.37M-15.67%-395.89M-6.03%-105.32M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 26.56%-83.54M8.85%-97.1M-5.22%-112.98M-12.16%-444.04M-10.50%-116.38M-14.20%-113.76M-7.23%-106.53M-17.21%-107.37M-15.67%-395.89M-6.03%-105.32M
Basic earnings per share 39.13%-0.2827.66%-0.3416.00%-0.4224.10%-1.8929.69%-0.4526.98%-0.4625.40%-0.4713.79%-0.5-11.66%-2.49-1.59%-0.64
Diluted earnings per share 39.13%-0.2827.66%-0.3416.00%-0.4224.10%-1.8929.69%-0.4526.98%-0.4625.40%-0.4713.79%-0.5-11.66%-2.49-1.59%-0.64
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data